Program
Four-factor Prothrombin Complex Concentrate
Also written as “BE1116”, “Beriplex® P/N (Kcentra)” and “4-Factor Prothrombin Complex Concentrate (4F-PCC)”.
Its studies are mostly in Wounds and Injuries · Hemophilia B · Blood Coagulation Disorders, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 41 open or running | phase 3since Jul 1, 2008 | Jul 1, 2008 | Apr 6, 2027phase 3 · NCT07094087 |
| Johnson & Johnson | 10 open or running | phase 1since Jul 28, 2020 | Jul 28, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2008First study: phase 3 study in Blood Coagulation DisordersNew to CSLCSL · NCT00708435 · 216 enrolled · United States, Belarus, Bulgaria and more
- Dec 4, 2008Phase 3 study in Hemophilia BCSL · NCT00803101 · 176 enrolled · United States, Belarus, Bulgaria and more
- Jul 28, 2020Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT04543383 · 52 enrolled · Netherlands
- Oct 3, 2022Phase 3 study in Wounds and InjuriesCSL · NCT05568888 · 1,366 enrolled · United States, Australia, United Kingdom
- Jul 14, 2025Phase 3 study in Complex Cardiovascular Surgery With Cardiopulmonary BypassCSL · NCT07094087 · 200 planned · United States, Canada, Japan and more
Ahead
- Apr 6, 2027Primary completion: phase 3 study in Complex Cardiovascular Surgery With Cardiopulmonary BypassCSL · NCT07094087
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass · United States, Canada, Japan and more | 3 | Recruiting | CSL | Apr 6, 2027 | 200 |
| NCT05568888Wounds and Injuries · United States, Australia, United Kingdom | 3 | Terminated | CSL | Oct 29, 2024 | 1,366 |
| NCT04543383Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Jun 7, 2023 | 52 |
| NCT00803101Hemophilia B · United States, Belarus, Bulgaria and more | 3 | Completed | CSL | Nov 2012 | 176 |
| NCT00708435Blood Coagulation Disorders · United States, Belarus, Bulgaria and more | 3 | Completed | CSL | Nov 2010 | 216 |
How it is read
Names in the registry
- “BE1116”, 2 entries
- “Beriplex® P/N (Kcentra)”, 2 entries
- “4-Factor Prothrombin Complex Concentrate (4F-PCC)”, 1 entry
Conditions, from the studies’ own filings
- Wounds and Injuries, 1 study
- Hemophilia B, 1 study
- Blood Coagulation Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.